NEW YORK, Sept. 26, 2018 /PRNewswire/
-- Neurotrope, Inc. (NASDAQ:
NTRP), a clinical-stage biopharmaceutical company developing
novel therapies for neurodegenerative diseases, including
Alzheimer's disease, today announced that updated data on its
lead compound, bryostatin, will be presented during the
11th Edition of Clinical Trials on Alzheimer's Disease
to be held in Barcelona, Spain from October
24th - 27th, 2018.
Details of the poster presentations are as follows:
|
Title:
|
Evidence of Sustained
Low Dose Bryostatin Efficacy for
Treatment of Alzheimer's Disease: Consistency of Multiple
Evaluation Analyses
|
|
Presentation
Theme:
|
Clinical trials:
Results
|
|
Date/Time:
|
Wednesday, October
24th, 2018: 1:00 – 4:00 PM
|
|
Location:
|
Palau de Catalunya
Conference Center
|
|
Abstract
Code:
|
LBP14
|
"Leveraging decades of work on the PKC pathway at NIH and other
leading institutions, bryostatin uses a novel mechanism of action
to generate new, mature synaptic connections and prevent neuronal
death in Alzheimer's disease models," said Dr. Daniel Alkon, President and Chief Scientific
Officer of Neurotrope. "We are highly encouraged by the translation
of this work to the clinic, with results from our Phase 2 study in
Alzheimer's disease showing promising early signals of clinical
improvement in moderate to severe AD patients, a population largely
neglected in drug development. We look forward to presenting these
new data at CTAD and to expanding on our understanding of
bryostatin in this difficult to treat population through our
ongoing Phase 2 study in AD."
About Neurotrope
Neurotrope is at the forefront of developing a new approach
to combating AD and other neurodegenerative diseases. The
Company's world-class science offers the potential to realize a
paradigm shift to overcome one of today's most challenging clinical
problems — finding a way to slow or even prevent the progression of
AD.
In addition to the Company's Phase 2 trial of Bryostatin-1 in
advanced AD, Neurotrope has also conducted preclinical studies of
Bryostatin-1 as a potential treatment for Stroke, Traumatic Brain
Injury, and Fragile X Syndrome, and Niemann-Pick Type C disease —
rare genetic diseases for which only symptomatic treatments are
currently available. The FDA has granted Orphan Drug Designation to
Neurotrope for Bryostatin-1 as a treatment for Fragile
X. Bryostatin-1 has already undergone testing in more than
1,500 people in cancer studies, thus creating a large safety data
base that will further inform clinical trial designs.
Please visit www.neurotrope.com for further
information.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. These forward-looking statements include statements
regarding the Phase 2 study and further studies, and continued
development of use of Bryostatin-1 for Alzheimer's dementia and
other cognitive diseases. Such forward-looking statements are
subject to risks and uncertainties and other influences, many of
which the Company has no control over. There can be no assurance
that the clinical program for Bryostatin-1 will be successful in
demonstrating safety and/or efficacy that we will not encounter
problems or delays in clinical development, or that Bryostatin-1
will ever receive regulatory approval or be successfully
commercialized. Actual results and the timing of certain events and
circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Additional factors that may influence or cause
actual results to differ materially from expected or desired
results may include, without limitation, the Company's inability to
obtain adequate financing, the significant length of time
associated with drug development and related insufficient cash
flows and resulting illiquidity, the Company's patent portfolio,
the Company's inability to expand the Company's business,
significant government regulation of pharmaceuticals and the
healthcare industry, lack of product diversification, availability
of the Company's raw materials, existing or increased
competition, stock volatility and illiquidity, and the
Company's failure to implement the Company's business plans or
strategies. These and other factors are identified and described in
more detail in the Company's filings with the SEC, including the
Company's Annual Report on Form 10-K for the year
ended December 31, 2017, and on Form 10-Q for the quarter
ended June 30, 2018. The Company
does not undertake to update these forward-looking statements.
Contact information:
Sam Martin / Ryan Baker
Argot Partners
212.600.1902
neurotrope@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/neurotrope-to-present-additional-phase-2-data-at-the-11th-edition-of-clinical-trials-on-alzheimers-disease-ctad2018-300719127.html
SOURCE Neurotrope, Inc.